Detalhe da pesquisa
1.
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 40(5): 509-518, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34664200
2.
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 38(4): 317-324, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31814080
3.
Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 38(5): 431-441, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31701471
4.
Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 40(5): 575, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35364758
5.
Response to Comment on "Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".
Pharmacoeconomics
; 38(6): 649-651, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32249398